Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Integrated molecular drivers coordinate biological and clinical states in melanoma.
Nature Genetics
Conway, Jake R JR; Dietlein, Felix F; Taylor-Weiner, Amaro A; AlDubayan, Saud S; Vokes, Natalie N; Keenan, Tanya T; Reardon, Brendan B; He, Meng Xiao MX; Margolis, Claire A CA; Weirather, Jason L JL; Haq, Rizwan R; Schilling, Bastian B; Stephen Hodi, F F; Schadendorf, Dirk D; Liu, David D; Van Allen, Eliezer M EM
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.
Bmc Cancer
Ottaiano, Alessandro A; Scala, Stefania S; Normanno, Nicola N; Napolitano, Maria M; Capozzi, Monica M; Rachiglio, Anna Maria AM; Roma, Cristin C; Trotta, Anna Maria AM; D'Alterio, Crescenzo C; Portella, Luigi L; Romano, Carmela C; Cassata, Antonino A; Casaretti, Rossana R; Silvestro, Lucrezia L; Nappi, Anna A; Tafuto, Salvatore S; Avallone, Antonio A; De Stefano, Alfonso A; Tamburini, Mario M; Picone, Carmine C; Petrillo, Antonella A; Izzo, Francesco F; Palaia, Raffaele R; Albino, Vittorio V; Amore, Alfonso A; Belli, Andrea A; Pace, Ugo U; Di Marzo, Massimiliano M; Chiodini, Paolo P; Botti, Gerardo G; De Feo, Gianfranco G; Delrio, Paolo P; Nasti, Guglielmo G
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
Scientific Reports
Borrero-Palacios, A A; Cebrián, A A; Gómez Del Pulgar, M T MT; García-Carbonero, R R; Garcia-Alfonso, P P; Aranda, E E; Elez, E E; López-López, R R; Cervantes, A A; Valladares, M M; Nadal, C C; Viéitez, J M JM; Guillén-Ponce, C C; Rodríguez, J J; Hernández, I I; García, J L JL; Vega-Bravo, R R; Puime-Otin, A A; Martínez-Useros, J J; Del Puerto-Nevado, L L; Rincón, R R; Rodríguez-Remírez, M M; Rojo, F F; García-Foncillas, J J
Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Plos One
Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.
Cancer Treatment Reviews
Ferris, Robert L RL; Lenz, Heinz-Josef HJ; Trotta, Anna Maria AM; García-Foncillas, Jesús J; Schulten, Jeltje J; Audhuy, François F; Merlano, Marco M; Milano, Gerard G
NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.
Molecular Oncology
Cirenajwis, Helena H; Lauss, Martin M; Ekedahl, Henrik H; Törngren, Therese T; Kvist, Anders A; Saal, Lao H LH; Olsson, Håkan H; Staaf, Johan J; Carneiro, Ana A; Ingvar, Christian C; Harbst, Katja K; Hayward, Nicholas K NK; Jönsson, Göran G
A Landscape of Pharmacogenomic Interactions in Cancer.
Cell
Iorio, Francesco F; Knijnenburg, Theo A TA; Vis, Daniel J DJ; Bignell, Graham R GR; Menden, Michael P MP; Schubert, Michael M; Aben, Nanne N; Gonçalves, Emanuel E; Barthorpe, Syd S; Lightfoot, Howard H; Cokelaer, Thomas T; Greninger, Patricia P; van Dyk, Ewald E; Chang, Han H; de Silva, Heshani H; Heyn, Holger H; Deng, Xianming X; Egan, Regina K RK; Liu, Qingsong Q; Mironenko, Tatiana T; Mitropoulos, Xeni X; Richardson, Laura L; Wang, Jinhua J; Zhang, Tinghu T; Moran, Sebastian S; Sayols, Sergi S; Soleimani, Maryam M; Tamborero, David D; Lopez-Bigas, Nuria N; Ross-Macdonald, Petra P; Esteller, Manel M; Gray, Nathanael S NS; Haber, Daniel A DA; Stratton, Michael R MR; Benes, Cyril H CH; Wessels, Lodewyk F A LFA; Saez-Rodriguez, Julio J; McDermott, Ultan U; Garnett, Mathew J MJ
Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients.
World Journal Of Gastrointestinal Oncology
Lo Nigro, Cristiana C; Ricci, Vincenzo V; Vivenza, Daniela D; Monteverde, Martino M; Strola, Giuliana G; Lucio, Francesco F; Tonissi, Federica F; Miraglio, Emanuela E; Granetto, Cristina C; Fortunato, Mirella M; Merlano, Marco Carlo MC
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
Bmc Bioinformatics
Melloni, Giorgio E M GE; de Pretis, Stefano S; Riva, Laura L; Pelizzola, Mattia M; Céol, Arnaud A; Costanza, Jole J; Müller, Heiko H; Zammataro, Luca L
Recurrent inactivating RASA2 mutations in melanoma.
Nature Genetics
Arafeh, Rand R; Qutob, Nouar N; Emmanuel, Rafi R; Keren-Paz, Alona A; Madore, Jason J; Elkahloun, Abdel A; Wilmott, James S JS; Gartner, Jared J JJ; Di Pizio, Antonella A; Winograd-Katz, Sabina S; Sindiri, Sivasish S; Rotkopf, Ron R; Dutton-Regester, Ken K; Johansson, Peter P; Pritchard, Antonia L AL; Waddell, Nicola N; Hill, Victoria K VK; Lin, Jimmy C JC; Hevroni, Yael Y; Rosenberg, Steven A SA; Khan, Javed J; Ben-Dor, Shifra S; Niv, Masha Y MY; Ulitsky, Igor I; Mann, Graham J GJ; Scolyer, Richard A RA; Hayward, Nicholas K NK; Samuels, Yardena Y
A highly recurrent RPS27 5'UTR mutation in melanoma.
Oncotarget
Dutton-Regester, Ken K; Gartner, Jared J JJ; Emmanuel, Rafi R; Qutob, Nouar N; Davies, Michael A MA; Gershenwald, Jeffrey E JE; Robinson, William W; Robinson, Steven S; Rosenberg, Steven A SA; Scolyer, Richard A RA; Mann, Graham J GJ; Thompson, John F JF; Hayward, Nicholas K NK; Samuels, Yardena Y
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
Bmc Cancer
Kjersem, Janne B JB; Skovlund, Eva E; Ikdahl, Tone T; Guren, Tormod T; Kersten, Christian C; Dalsgaard, Astrid M AM; Yilmaz, Mette K MK; Fokstuen, Tone T; Tveit, Kjell M KM; Kure, Elin H EH
A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.
Molecular Cancer Therapeutics
Xia, Junfeng J; Jia, Peilin P; Hutchinson, Katherine E KE; Dahlman, Kimberly B KB; Johnson, Douglas D; Sosman, Jeffrey J; Pao, William W; Zhao, Zhongming Z